Researchers have made a discovery about GLP-1 drugs, which could lead to personalized treatments for individuals. A study found that higher-dosage GLP-1 agonists produced greater improvements in cardiometabolic health. Further details about this study are available from KTSM 9 News, for those interested in learning more about the potential advancements in GLP-1 drug treatment.
Recent coverage curated from local and regional sources.
EL PASO, Texas (Border Report) — An El Paso woman pleaded guilty after sedating children with THC-laced gummies and smuggling them across th…
EL PASO, Texas (KTSM) -- A New Mexico State University professor of psychology and kinesiology is leading a nationwide initiative to improve…
The higher-dosage GLP-1 agonists largely engendered greater cardiometabolic improvements.
Want to upgrade the place where you spend most of your workdays? Check out this sale!
The number of migrants who were living unauthorized in the United States swelled to an estimated record 15.8 million in 2024, up from 11 mil…
This means no new robot vacuums from brands such as Roborock and Samsung – and the ban will also affect robot lawnmowers.
The incidents involved three different Claude models — Opus 4.7, Mythos and an unnamed internet research test model.
Por Jennifer Hansler, CNN El Departamento de Estado de Estados Unidos anunció que ahora ofrecerá pasaportes conmemorativos con una imagen de…
The rechargeable hand warmers have caused 15 fires, 350 burn injuries and the death of an 83-year-old man in San Diego.
Por Federico Leiva, CNN en Español El 10 de enero de 2012, Puerto Príncipe tembló como nunca antes. El terremoto de 7,0 fue devastador. Tiró…
EL PASO, Texas (KVIA) - The Heart Gallery of El Paso's mission is to help children in foster care find loving permanent homes. The organizat…
By Jessie Yeung, Yumi Asada, CNN (CNN) — Japan is launching a new centralized intelligence body for the first time since World War II – a co…
Free weekly digest. Local news that actually matters — no spam, no clickbait, easy unsubscribe.
By subscribing you agree to our privacy policy. We never sell your data.